| Item Type | Name |
|
Concept
|
Neoplastic Stem Cells
|
|
Concept
|
Cell Adhesion
|
|
Concept
|
Dendritic Cells
|
|
Concept
|
Cell Cycle Proteins
|
|
Concept
|
Carcinoma, Transitional Cell
|
|
Concept
|
Cell Differentiation
|
|
Concept
|
Cell Proliferation
|
|
Concept
|
Carcinoma, Renal Cell
|
|
Concept
|
Neoplastic Cells, Circulating
|
|
Concept
|
Cell Line, Tumor
|
|
Concept
|
Cell Count
|
|
Academic Article
|
Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.
|
|
Academic Article
|
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy.
|
|
Academic Article
|
Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?
|
|
Academic Article
|
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma.
|
|
Academic Article
|
Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach.
|
|
Academic Article
|
Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program.
|
|
Academic Article
|
Designing novel immunocombinations in metastatic renal cell carcinoma.
|
|
Academic Article
|
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer.
|
|
Academic Article
|
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
|
|
Academic Article
|
Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice.
|
|
Academic Article
|
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study.
|
|
Academic Article
|
Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?
|
|
Academic Article
|
Tivozanib for the treatment of renal cell carcinoma.
|
|
Academic Article
|
Circulating tumor cells in genitourinary tumors.
|
|
Academic Article
|
Re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269-76: Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation.
|
|
Academic Article
|
Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution.
|
|
Academic Article
|
Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis.
|
|
Academic Article
|
The prospect of precision therapy for renal cell carcinoma.
|
|
Academic Article
|
Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies.
|
|
Academic Article
|
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer.
|
|
Academic Article
|
Liquid biopsies in renal cell carcinoma with focus on epigenome analysis.
|
|
Academic Article
|
Emerging Immunotargets and Immunotherapies in Prostate Cancer.
|
|
Academic Article
|
Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy.
|
|
Academic Article
|
Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer.
|
|
Academic Article
|
New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?
|
|
Academic Article
|
Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives.
|
|
Academic Article
|
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications.
|
|
Academic Article
|
Immunotherapy for urothelial cancer: from the diagnostic pathologist's point of view.
|
|
Academic Article
|
Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma.
|
|
Academic Article
|
Editorial: Emerging Immunotargets in Genitourinary Tumors.
|
|
Academic Article
|
Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside.
|
|
Academic Article
|
Re: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al. Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer: A Non-randomised, Open-label, Dose-finding, and Dose-expansion Phase 1b Trial. Lancet Oncol 2018;19:405-15.
|
|
Academic Article
|
Optimizing renal function and outcome of patients with cT2 renal cell carcinoma.
|
|
Academic Article
|
Renal cell carcinoma in one year: Going inside the news of 2017 - A report of the main advances in RCC cancer research.
|
|
Academic Article
|
Re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. N Engl J Med 2018;379:417-27: CARMENA Trial: Is This the End of Cytoreductive Nephrectomy in Patients with Clear-cell Renal Cell Carcinoma?
|
|
Academic Article
|
Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer.
|
|
Academic Article
|
Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy.
|
|
Academic Article
|
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
|
|
Academic Article
|
Metabolic alterations in renal cell carcinoma.
|
|
Academic Article
|
Immunotherapy and Radiation Therapy in Renal Cell Carcinoma.
|
|
Academic Article
|
Prophylactic use of mTOR inhibitors and other immunosuppressive agents in heart transplant patients.
|
|
Academic Article
|
PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay.
|
|
Academic Article
|
Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 1 - kidney cancer.
|
|
Academic Article
|
PD-L1 Inhibitors for the Treatment of Prostate Cancer.
|
|
Academic Article
|
Metabolic phenotype of bladder cancer.
|
|
Academic Article
|
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis.
|
|
Academic Article
|
Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers.
|
|
Academic Article
|
Toward a genome-based treatment landscape for renal cell carcinoma.
|
|
Academic Article
|
Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End.
|
|
Academic Article
|
Emerging Immunotargets in Metastatic Renal Cell Carcinoma.
|
|
Academic Article
|
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
|
|
Academic Article
|
Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma.
|
|
Academic Article
|
Reply to Michael Staehler, Dena Battle, Axel Bex, Hans Hammers, and Daniel George's Letter to the Editor re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. Eur Urol 2018;74:842-3: Lymphocyte Phenotype and Timing of Radical Nephrectomy in Patients Treated with Immunocheckpoint Inhibitors for Renal Cell Carcinoma.
|
|
Academic Article
|
Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma.
|
|
Academic Article
|
Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort.
|
|
Academic Article
|
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors.
|
|
Academic Article
|
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss.
|
|
Academic Article
|
Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?
|
|
Academic Article
|
Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions.
|
|
Academic Article
|
Circulating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future Challenges.
|
|
Academic Article
|
Adjuvant therapy in renal cell carcinoma-is pharmacogenomics assessment another element to select our patients?
|
|
Academic Article
|
Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor.
|
|
Academic Article
|
Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma.
|
|
Academic Article
|
Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma.
|
|
Academic Article
|
Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis.
|
|
Academic Article
|
Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma.
|
|
Academic Article
|
Liquid biopsy in the clinical management of bladder cancer: current status and future developments.
|
|
Academic Article
|
Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 2 - prostate and bladder cancer.
|
|
Academic Article
|
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
|
|
Academic Article
|
Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?
|
|
Academic Article
|
Emerging Immunotargets in Bladder Cancer.
|
|
Academic Article
|
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer.
|
|
Academic Article
|
An Overview of Emerging Immunotargets of Genitourinary Tumors.
|
|
Academic Article
|
The route to personalized medicine in bladder cancer: where do we stand?
|
|
Academic Article
|
The origin of prostate metastases: emerging insights.
|
|
Academic Article
|
New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials.
|
|
Academic Article
|
Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder.
|
|
Academic Article
|
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors.
|
|
Academic Article
|
Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy.
|
|
Academic Article
|
Is There a Role for Immunotherapy in Prostate Cancer?
|
|
Academic Article
|
Tp53 and its potential therapeutic role as a target in bladder cancer.
|
|
Academic Article
|
Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States.
|
|
Academic Article
|
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications.
|
|
Academic Article
|
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?
|
|
Academic Article
|
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.
|
|
Academic Article
|
Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
|
|
Academic Article
|
A brand-new CAR for macrophages: is it time to fire up the engines of a new era for the treatment of renal cell carcinoma?
|
|
Academic Article
|
Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?
|
|
Academic Article
|
Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials.
|
|
Academic Article
|
Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma.
|
|
Academic Article
|
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic review.
|
|
Academic Article
|
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis.
|
|
Academic Article
|
Towards a new WHO classification of renal cell tumor: what the clinician needs to know-a narrative review.
|
|
Academic Article
|
Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages.
|
|
Academic Article
|
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis.
|
|
Academic Article
|
Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial.
|
|
Academic Article
|
Risk of selected gastrointestinal toxicities in metastatic renal cell carcinoma patients treated with immuno-TKI combinations: a meta-analysis.
|
|
Academic Article
|
The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory?
|
|
Academic Article
|
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials.
|
|
Academic Article
|
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study.
|
|
Academic Article
|
An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma.
|
|
Academic Article
|
Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study.
|
|
Academic Article
|
Metabolomic Profiling in Renal Cell Carcinoma Patients: News and Views.
|
|
Academic Article
|
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma.
|
|
Academic Article
|
Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials.
|
|
Concept
|
Cell Plasticity
|
|
Concept
|
Cell-Free Nucleic Acids
|
|
Concept
|
Costimulatory and Inhibitory T-Cell Receptors
|
|
Concept
|
Programmed Cell Death 1 Receptor
|
|
Academic Article
|
Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis.
|
|
Academic Article
|
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib.
|
|
Academic Article
|
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors.
|
|
Academic Article
|
Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison.
|
|
Academic Article
|
Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: a meta-analysis.
|